Jules Desmeules

University of Geneva

H指数:50

被引数:9,500

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A randomised, double-blind, placebo-controlled crossover trial on cannabinoid-based medication for behavioural disorders in old patients with severe dementia: the study results

一项关于大麻素基药物治疗严重痴呆老年患者行为障碍的随机、双盲、安慰剂对照交叉试验：研究结果

Age and Ageing

IF7.1

2026-08-180

OAAI

Evaluation of Pupillometry for CYP2D6 Phenotyping in Children Treated with Tramadol

曲马多治疗儿童CYP2D6表型的瞳孔测量评价

PHARMACEUTICALS

IF4.8

2023-08-300

OAAI

Osteoporosis treatment and pain relief: A scoping review

骨质疏松症治疗和疼痛缓解: 范围审查

EUROPEAN JOURNAL OF PAIN

IF3.4

2023-07-058

PRE

Safety Surveillance During Drug Development: Comparative Evaluation of Existing Regulations

ADVANCES IN THERAPY

IF4

2023-04-053

OAAI

Joint Analysis of Phenotypic and Genomic Diversity Sheds Light on the Evolution of Xenobiotic Metabolism in Humans

表型和基因组多样性的联合分析揭示了人类异种生物代谢的进化

GENOME BIOLOGY AND EVOLUTION

IF2.8

2022-11-292

OAAI

Cannabinoids for behavioral symptoms in severe dementia: Safety and feasibility in a long-term pilot observational study in nineteen patients

FRONTIERS IN AGING NEUROSCIENCE

IF4.5

2022-09-2912

OAAI

Drug metabolic enzyme genotype-phenotype discrepancy: High phenoconversion rate in patients treated with antidepressants

BIOMEDICINE & PHARMACOTHERAPY

IF7.5

2022-08-0114

OAAI

Adverse Drug Reactions Due to Opioid Use in Oldest-Old Patients Visiting the Emergency Unit of the Geneva Geriatric Hospital

JOURNAL OF FRAILTY & AGING

IF3.3

2022-07-011

PRE

Uncovering a Genetic Polymorphism Located in Huntingtin Associated Protein 1 in Modulation of Central Pain Sensitization Signaling Pathways

FRONTIERS IN NEUROSCIENCE

IF3.2

2022-06-286

OAAI

Dexamethasone exposure in normal-weight and obese hospitalized COVID-19 patients: An observational exploratory trial

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2022-06-158

Evaluation of CYP1A2 activity: Relationship between the endogenous urinary 6-hydroxymelatonin to melatonin ratio and paraxanthine to caffeine ratio in dried blood spots

CYP1A2活性的评估: 干血斑中内源性尿6-羟基褪黑激素与褪黑激素之比与副黄嘌呤与咖啡因之比之间的关系

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2022-03-262

Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting

JOURNAL OF PERSONALIZED MEDICINE

IF3

2022-03-2419

OAAI

Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2021-11-1714

OAAI

Impact of SARS-CoV-2 Infection (COVID-19) on Cytochromes P450 Activity Assessed by the Geneva Cocktail

SARS-CoV-2感染 (新型冠状病毒肺炎) 对日内瓦鸡尾酒评估的细胞色素P450活性的影响

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2021-09-2144

OAAI

Metabolomics reveals biomarkers in human urine and plasma to predict cytochrome P450 2D6 (CYP2D6) activity

代谢组学揭示人尿和血浆中的生物标志物以预测细胞色素P450 2D6 (CYP2D6) 活性

BRITISH JOURNAL OF PHARMACOLOGY

IF7.7

2021-09-0922

Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients

DRUGS

IF14.4

2021-07-0133

OAAI

Prevalence of Polypharmacy and Inappropriate Medication in Adults With Intellectual Disabilities in a Hospital Setting in Switzerland

FRONTIERS IN PSYCHIATRY

IF3.2

2021-06-2511

OAAI

The 1β-Hydroxy-Deoxycholic Acid to Deoxycholic Acid Urinary Metabolic Ratio: Toward a Phenotyping of CYP3A Using an Endogenous Marker?

JOURNAL OF PERSONALIZED MEDICINE

IF3

2021-02-206

OAAI

Impact of Acute Inflammation on Cytochromes P450 Activity Assessed by the Geneva Cocktail

日内瓦鸡尾酒评估急性炎症对细胞色素P450活性的影响

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2021-01-0856

OAAI

Evaluation of Phenotypic and Genotypic Variations of Drug Metabolising Enzymes and Transporters in Chronic Pain Patients Facing Adverse Drug Reactions or Non-Response to Analgesics: A Retrospective Study

JOURNAL OF PERSONALIZED MEDICINE

IF3

2020-10-2710

OAAI

Jules Desmeules

个人简介

教育背景

工作经历

荣誉奖项

研究方向